Pancreatic neuroendocrine tumors

Endocrine Research

Volumn 36, Issue 1, 2011, Pages 35-43

  Batcher, Elizabeth ^a,b   Madaj, Paul ^a,b   Gianoukakis, Andrew G ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gastrinoma; Glucagonoma; Insulinoma; Neuroendocrine tumor; Somatostatinoma; VIPoma

Indexed keywords

ANTINEOPLASTIC AGENT; C PEPTIDE; CHROMOGRANIN A; DANAZOL; GASTRIN; GLUCAGON; GLUCOSE; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PENTETREOTIDE; PROINSULIN; PROTON PUMP INHIBITOR; RECOMBINANT ALPHA INTERFERON; SECRETIN; SOMATOSTATIN;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOEMBOLIZATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DIAPHORESIS; ENDOSCOPIC ECHOGRAPHY; FAMILIAL CANCER; FOLLOW UP; GASTRIN BLOOD LEVEL; GASTRINOMA; GENETIC SCREENING; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULINOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN BLOOD LEVEL; SOMATOSTATINOMA; VASOACTIVE INTESTINAL PEPTIDEOMA; VISUAL DISORDER; VON HIPPEL LINDAU DISEASE;

GASTRINOMA; GASTRINS; GLUCAGON; GLUCAGONOMA; HORMONES; HUMANS; HYPOGLYCEMIA; INSULINOMA; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SOMATOSTATINOMA; VASOACTIVE INTESTINAL PEPTIDE; VIPOMA;

EID: 78651435915     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2010.525085     Document Type: Article

References (34)

1. Boushey RP, Drucker DJ. Gastrointestinal hormones and gut endocrine hormones. In: Williams K, ed. Textbook of Endocrinology. 11th ed (pp. 1777-1796). Philadelphia: WB Saunders; 2008.
2. Abood GJ, Go A, Malhotra D, Shoup M. The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2009;89:249-266.
3. Davies K, Conlon KC.Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 2009;11:119-127.
4. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-1492.
5. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991;36:933-942.
6. Howard TJ, Stabile BE, Zinner MJ, Chang S, Bhagavan BS, Passaro E Jr. Anatomic distribution of pancreatic endocrine tumors. Am J Surg 1999;159:258-264.
7. Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 1995;80:2273-2278.
8. Frankel WL. Update on pancreatic endocrine tumors. Arch Pathol Lab Med 2006;130:963-966.
9. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 2005;128:1668-1684.
10. Hopfner M, Schuppan D, Scherubl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J Gastroenterol 2008;14:2461-2473.
11. Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am 2009;89:1105-1121.
12. Nikfarjam M, Warshaw AL, Axelrod L, et al Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008;247:165-172.
13. Cryer PE, Axelrod L, Grossman AB, et al Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009;94:709-728.
14. Horwitz DL, Rubenstein AH, Reynolds C, Molnar GD, Yanaihara N. Prolonged suppression of insulin release by insulin-induced hypoglycemia: demonstration by C-peptide assay. Horm Metab Res 1975;7:449-452.
15. Ipp E, Sinai Y, Forster B, et al A glucose reduction challenge in the differential diagnosis of fasting hypoglycemia: a two-center study. J Clin Endocrinol Metab 1990;70:711-717.
16. Service FJ, Horwitz DL, Rubenstein AH, et al C-peptide suppression test for insulinoma. J Lab Clin Med 1977;90:180-186.
17. Turner RC, Heding LG. Plasma proinsulin, C-peptide and insulin in diagnostic suppression tests for insulinomas. Diabetologia 1977;13:571-577.
18. Placzkowski KA, Vella A, Thompson GB, et al Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 2009;94:1069-1073.
19. Brandi ML, Gagel RF, Angeli A, et al Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
20. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004;83:43-83.
21. Mittendorf EA, Shifrin AL, Inabnet WB, Libutti SK, McHenry CR, Demeure MJ. Islet cell tumors. Curr Prob Surg 2006;43:685-765.
22. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006;85:295-330.
23. Morrow EH, Norton JA. Surgical management of Zollinger-Ellison syndrome; state of the art. Surg Clin North Am 2009;89:1091-1103.
24. Smith SL, Branton SA, Avino AJ,et al Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 1998;124:1050-1055.
25. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001;321:306-320.
26. Higgins GA, Recant L, Fischman AB. The glucagonoma syndrome: surgically curable diabetes. Am J Surg 1979;137:142-148.
27. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 2008;15:409-427.
28. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008;14:5377-5384.
29. Stridsberg M, Eriksson B, Fellstrom B, Kristiansson G, Tiensuu Janson E. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept 2007;139:80-83.
30. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000;62(Suppl. 1):33-38.
31. Abou-Saif A, Gibril F, Ojeaburu JV, et al Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 2003;98:249-261.
32. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995;144:49-59.
33. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003;10:437-450.
34. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113: 1807-1843.